Quantcast

Industry news that matters to you.  Learn more

Plavix Biomarker Test Can Improve Patient Outcomes

In January, the Agency for Healthcare Research and Quality (AHRQ) released “Outpatient Prescription Anticoagulants Utilization and Expenditures for the U.S. Civilian Noninstitutionalized Population Age 18 and Older 2007,” a study from its October 2009 Medical Expenditure Panel Survey (MEPS). This report found that anticoagulant drugs were prescribed to more than 4.2 million Americans at a cost of $900 million and were paid for by patients and/or third-party payers.

Critical Health Unveils a Biomarker for Diabetic Retinopathy Progression at the EuRetina Congress in Paris

Critical Health, a provider of innovative decision support software for ophthalmology, will showcase at the EuRetina Congress in Paris, France (Booth 222B). Recently granted a European IT Excellence Award, Retmarker allows physicians to have a more precise source of information, which is not prone to errors related to the complexity in the estimations of lesion areas present in each subfield of the retinography (color fundus photograph).

The Cancer Biomarker Conundrum: Too Many False Discoveries

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

NIH to Fund Research into Environmental Stress Biomarkers

The National Institute of Environmental Health Sciences will lead a program to give a total of $2.6 million for five or six projects over two years that seek to validate candidate biomarkers and technologies that measure biological responses to chemical toxicants and other environmental stressors.

CWRU Dental Researchers Discover Human Beta Defensins-3 Ignite in Oral Cancer Growth

Detecting oral cancer in its earliest stages can save the lives of the nearly 40,500 people diagnosed annually. But early detection has been difficult.

Case Western Reserve University School of Dental Medicine researchers discovered a biomarker, called human beta defensin-3 (hBD-3), which may serve as an early warning. The defensin is present in all oral cancers and associated with the early stages of oral cancer.